Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; and R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d and R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.

Abstract: The specification relates to compounds of Formula (1): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cancer.

Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; and R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d and R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.

Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; and R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d and R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.

Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; and R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d and R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.

Abstract: Disclosed are compounds of formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of treating cancer or a respiratory inflammatory disease using the same: wherein R1 is selected from hydrogen, —CH3 and —(C?O)CH(R1a)NH2; R1a is C1-C4 alkyl; Y is —(CH2)n— or —(C?O)—; n is an integer selected from 1 and 2; R2 is selected from hydrogen, —CH3 and —(C?X)R4 and R3 is hydrogen or —CH3; or R2 and R3, together with the nitrogen to which they are attached, are linked to form a 6-membered heterocyclic ring; X is NH or O; R4 is —CH3 or —[CH(R4a)]mNH2; m is an integer selected from 0 or 1; and R4a is hydrogen or C1-C6 alkyl.

Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d; R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.

Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, to present a video. One of the methods includes obtaining loan transfer information for a user. The method includes selecting non-personalized content, at least some of the non-personalized content selected based on the loan transfer information. The method includes generating a user specific video using the loan transfer information and the selected non-personalized content. The method also includes providing the user specific video to the user.

Abstract: Disclosed are compounds of formula (Ib) or (Vc), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ib) or (Vc) and methods of using the same for treating cancer, respiratory inflammatory disease, and inhibiting arginase; wherein R is —H or —C(O)CH(R1a)NHR1b; and R1a is selected from —H, —(C1-C4) alkyl and CH2OR1c; R1b is —H; or alternatively, R1a and R1b, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1c is H or —CH3.

Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d; R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.

Abstract: The present invention provides compounds and compositions for inhibiting Vif and methods for treating viral infection, e.g., HIV infection.

Abstract: An apparatus for displaying an object is provided. The apparatus includes a body portion having a base end for engaging a display surface, such as a wall, and an opposite mounting end for engaging the object to be displayed. The apparatus also includes, at its base end, an attachment mechanism for securely affixing the apparatus to the display surface. The apparatus further includes, at its mounting end, a hub for releasably mounting the object being displayed onto the mounting end of the apparatus. A method of displaying an object is also provided.

Abstract: An audio encoding system includes quantization, phase matching, compressed domain processing and other improvements enabling high fidelity, low bit rate encoding systems to be formed. In a preferred embodiment a novel transient detector is used to divide an audio source into transient, low frequency non-transient and high frequency non-transient regions. Low frequency non-transients are sinusoid modeled and the residual is low frequency noise modeled. Transients are transform coded and high frequency non-transients and transform coded residual is high frequency noise modeled. The preferred embodiment also includes novel sinusoid, transform coded and noise quantization, among other methods for providing high fidelity data reduction and for interfacing sinusoid modeling and transform coding. Compressed domain time compression and expansion are further achieved with no detrimental effect on transients.